Press Release Archives

Press Release

June 11, 2025

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche…

Gerard Caelles 0

Love0

Press Release

March 13, 2025

SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients…

Maneko 0

Love0

Press Release

December 12, 2024

SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease

SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with…

Maneko 0

Love0

Press Release

April 10, 2024

SpliceBio to Attend and Present at Key Scientific and Investor Conferences in April to June 2024

BARCELONA, 10 April 2024 – SpliceBio, a genetic medicines company harnessing Protein Splicing to develop…

Maneko 0

Love0

Press Release

January 3, 2024

SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer

Dr. Girach is a world-renowned specialist in the field of ophthalmology and gene therapy Appointment…

Maneko 0

Love0

Press Release

October 17, 2023

SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease

SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus…

Maneko 0

Love0

Press Release

June 20, 2023

SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program

Dr. Favre brings extensive experience in gene therapy, immunology and drug development Appointment comes at…

Maneko 0

Love0

Press Release

January 26, 2023

Splice Bio awarded with a “Colaboración Público-Privada” grant

BARCELONA, January 26, 2023 – SpliceBio, a genetic medicines company on a mission to expand…

Maneko 0

Love0

Press Release

February 16, 2022

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

Financing co-led by UCB Ventures and Ysios Capital with participation by New Enterprise Associates, Gilde…

Maneko 0

Love0

Press Release

January 21, 2021

Splice Bio appoints Jean-Philippe Combal as Chairman of the Board of Directors

BARCELONA, January 21, 2021 – Splice Bio, a gene therapy company based on technology developed…

Maneko 0

Love0

Press Release

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease

SpliceBio to Attend and Present at Key Scientific and Investor Conferences in April to June 2024

SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer

SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease

SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program

Splice Bio awarded with a “Colaboración Público-Privada” grant

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

Splice Bio appoints Jean-Philippe Combal as Chairman of the Board of Directors

Recent Posts

Recent Comments

Categories